Screenpoint Transpara Child Page

Screening mammography is an effective screening tool, but has limitations. With over 30 peer reviewed publications that have demonstrated Transpara's clinical effectiveness, it is a trusted choice of luminary institutions around the world, including radiology thought-leaders at RadboudUMC and Johns Hopkins.

Transpara is trusted by hundreds of sites in dozens of countries to tackle the following key challenges:

• Volume overload with DBT acquisition (typically single reader).
• Volume overload when reading FFDM acquisition (double reading environment).
• Workforce capacity constraints in breast imaging reading – meeting need for screening mammography reading that is quickly outpacing radiologist capacity.

With Transpara, radiologists get:
• A clear, simple report that provides image-based risk categorization to gain improved workflow.
• Greater confidence, particularly in dense breast tissue – Transpara provides decision support even where mammography is hardest, in the half of women with denser breast tissue.
• Risk-assessment with image-based risk enables both a proven-accurate snapshot of risk as well as the opportunity to track risk over time to find red-flags in individual trends.

Transpara has the following regulatory clearances:
• FDA 510(k) USA
• MDR CE Europe
• TGA Australia
• Medsafe New Zealand
• UKCA United Kingdom
• MedDO Switzerland
• CMDR Canada
• SFDA Saudi Arabia

• Workflow: First Breast AI Randomized Controlled Trial was done using Transpara and showed a safe and effective 44% reduction in reading workload with a 20% increase in cancer detection and no material change in recall rate.¹

Other studies show that DBT reading time on studies identified with low AI scores for cancer can take 30% less time to read with Transpara². Also, in a trial with a second reader replaced with Transpara, there was increased cancer detection and a stable recall rate.³

• Confidence: Radiologist cancer detection accuracy with decision support from Transpara improves regardless of experience and background.²

• Risk Assessment: A May 2023 Journal of Clinical Oncology paper from Mayo and UCSF demonstrated that a 1 point increase in Transpara score (when using a 10 point scale) represented an approximate 20% increased risk of invasive cancer when used as a long-term risk measure.⁴

• Results: Studies show improvements in interval cancer detection, reading time, and detection in dense breast tissue.² ⁴

ScreenShot-of-Transpara-report-Elevated-768x458

ScreenShot-of-Transpara-report-Intermediate-768x434

ScreenShot-of-Transpara-report-Low-768x493

¹Lång K, Viktoria Josefsson, Larsson AM, Larsson S, Högberg C, Sartor H, et al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncology. 2023 Aug 1;24(8):936–44.

²van Winkel SL, Rodríguez-Ruiz A, Appelman L, Gubern-Mérida A, Karssemeijer N, Teuwen J, et al. Impact of artificial intelligence support on accuracy and reading time in breast tomosynthesis image interpretation: a multi-reader multi-case study. European Radiology. 2021 May 4;

³Balta C, Rodriguez-Ruiz A, Mieskes C, Karssemeijer N, Heywang-Kobrunner SH. Going from double to single reading for screening exams labeled as likely normal by AI: what is the impact? Spie Digital Library. 2020 May 22;

⁴Vachon, et al, Journal of Clinical Oncology, 2023: Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer

ScreenPoint Medical Transpara

Overview

Features

Benefits

Image examples

Book a meeting